These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 38410967)
1. Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells. Luan Q; Pulido I; Isagirre A; Carretero J; Zhou J; Shimamura T; Papautsky I Lab Chip; 2024 Mar; 24(7):2025-2038. PubMed ID: 38410967 [TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies. Luan Q; Becker JH; Macaraniag C; Massad MG; Zhou J; Shimamura T; Papautsky I Lab Chip; 2022 Jun; 22(12):2364-2375. PubMed ID: 35551303 [TBL] [Abstract][Full Text] [Related]
3. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination. Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255 [TBL] [Abstract][Full Text] [Related]
4. Activity and resistance to KRAS Ye W; Lu X; Qiao Y; Ou WB Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697 [TBL] [Abstract][Full Text] [Related]
5. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046 [TBL] [Abstract][Full Text] [Related]
6. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. Manabe T; Bivona TG J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243 [TBL] [Abstract][Full Text] [Related]
8. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Li YF; Gao Y; Liang BW; Cao XQ; Sun ZJ; Yu JH; Liu ZD; Han Y Neoplasma; 2020 Mar; 67(2):430-437. PubMed ID: 31973535 [TBL] [Abstract][Full Text] [Related]
9. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer. Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673 [TBL] [Abstract][Full Text] [Related]
10. The KRAS-G12C inhibitor: activity and resistance. Liu J; Kang R; Tang D Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411 [TBL] [Abstract][Full Text] [Related]
12. Characterization of 3D NSCLC Cell Cultures with Fibroblasts or Macrophages for Tumor Microenvironment Studies and Chemotherapy Screening. Garnique ADMB; Machado-Santelli GM Cells; 2023 Dec; 12(24):. PubMed ID: 38132110 [TBL] [Abstract][Full Text] [Related]
13. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674 [TBL] [Abstract][Full Text] [Related]
14. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640 [TBL] [Abstract][Full Text] [Related]
15. Histo-pillar strip for optimal histogel block construction and biomarker analysis in 3D-lung cancer patient-derived organoids. Lee SY; Lee E; Ryu JO; Kim K; Hwang Y; Ku B; Moon SW; Moon MH; Kim KS; Hyun K; Lim JU; Park CK; Kim SW; Yeo CD; Lee DW; Kim SJ Biofabrication; 2024 Aug; 16(4):. PubMed ID: 39074508 [TBL] [Abstract][Full Text] [Related]
16. Adagrasib: a novel inhibitor for Guo MZ; Marrone KA; Spira A; Rosner S Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216 [TBL] [Abstract][Full Text] [Related]
17. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Pamarthy S; Sabaawy HE Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953 [TBL] [Abstract][Full Text] [Related]
18. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment. Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742 [TBL] [Abstract][Full Text] [Related]
19. First-in-Humans PET Imaging of Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842 [TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]